Suppr超能文献

分子成像:当今可用的技术

Molecular imaging: what can be used today.

作者信息

Jager P L, de Korte M A, Lub-de Hooge M N, van Waarde A, Koopmans K P, Perik P J, de Vries E G E

机构信息

Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center, Groningen, The Netherlands.

出版信息

Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S27-32. doi: 10.1102/1470-7330.2005.0023.

Abstract

Biochemical cellular targets and more general metabolic processes in cancer cells can be visualised. Extensive data are available on molecular imaging in preclinical models. However, innovative tracers move slowly to the clinic. This review provides information on the currently available methods of metabolic imaging, especially using PET in humans. The uptake mechanisms of tracer methods and a brief discussion of the more 'molecular' targeted methods are presented. The main focus is on the different classes of tracers and their application in various types of cancer within each class of tracers, based on the current literature and our own experience. Studies with [18F]FDG (energy metabolism), radiolabelled amino acids (protein metabolism), [18F]FLT (DNA metabolism), [11C]choline (cell membrane metabolism) as general metabolic tracer methods and [18F]DOPA (biogenic amine metabolism) as a more specific tracer method are discussed. As an example, molecular imaging methods that target the HER2 receptor and somatostatin receptor are described.

摘要

癌细胞中的生化细胞靶点和更一般的代谢过程可以可视化。在临床前模型中,关于分子成像有大量数据。然而,创新型示踪剂进入临床的速度较慢。本综述提供了有关当前可用的代谢成像方法的信息,特别是在人体中使用正电子发射断层扫描(PET)的情况。介绍了示踪剂方法的摄取机制,并对更具“分子”靶向性的方法进行了简要讨论。主要基于当前文献和我们自己的经验,重点关注不同类别的示踪剂及其在各类示踪剂中的各种癌症类型中的应用。讨论了使用[18F]氟代脱氧葡萄糖(能量代谢)、放射性标记氨基酸(蛋白质代谢)、[18F]氟代胸苷(DNA代谢)、[11C]胆碱(细胞膜代谢)作为一般代谢示踪剂方法,以及[18F]多巴(生物胺代谢)作为更特异性示踪剂方法的研究。作为示例,描述了靶向人表皮生长因子受体2(HER2)和生长抑素受体的分子成像方法。

相似文献

1
Molecular imaging: what can be used today.
Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S27-32. doi: 10.1102/1470-7330.2005.0023.
2
PET and PET/CT in pediatric oncology.
Semin Nucl Med. 2007 Sep;37(5):316-31. doi: 10.1053/j.semnuclmed.2007.04.001.
6
Imaging of cell proliferation: status and prospects.
J Nucl Med. 2008 Jun;49 Suppl 2:64S-80S. doi: 10.2967/jnumed.107.046391.
8
Imaging pharmacodynamics in oncology: the potential significance of "flares".
Ann Nucl Med. 2010 Apr;24(3):137-47. doi: 10.1007/s12149-009-0332-7. Epub 2010 Jan 13.
9
The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Ann Nucl Med. 2008 Jul;22(6):533-8. doi: 10.1007/s12149-007-0142-8. Epub 2008 Aug 1.
10
[Fluorine-18 in radiopharmacy].
Ann Pharm Fr. 2008 Jan;66(1):60-5. doi: 10.1016/j.pharma.2007.12.002. Epub 2008 Mar 28.

引用本文的文献

1
Comparison of F-NaF PET/CT and F-FDG PET/CT for Detection of Skull-Base Invasion and Osseous Metastases in Nasopharyngeal Carcinoma.
Contrast Media Mol Imaging. 2018 Sep 5;2018:8271313. doi: 10.1155/2018/8271313. eCollection 2018.
2
F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.
Jpn J Radiol. 2018 Sep;36(9):544-550. doi: 10.1007/s11604-018-0755-y. Epub 2018 Jun 25.
6
Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin.
Mol Imaging Biol. 2013 Feb;15(1):79-86. doi: 10.1007/s11307-012-0561-3.
7
Feasibility evaluation of radioimmunoguided surgery of breast cancer.
Int J Mol Imaging. 2012;2012:545034. doi: 10.1155/2012/545034. Epub 2012 Feb 20.
8
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.
Br J Radiol. 2011 Dec;84 Spec No 2(Spec Iss 2):S179-95. doi: 10.1259/bjr/76389842.
10
Advancing molecular imaging: a chairman's perspective on how radiology can meet the challenge.
Pediatr Radiol. 2011 Feb;41(2):141-3. doi: 10.1007/s00247-010-1777-5. Epub 2010 Aug 31.

本文引用的文献

4
PET imaging of cellular proliferation.
Radiol Clin North Am. 2005 Jan;43(1):153-67. doi: 10.1016/j.rcl.2004.09.005.
6
[18F]FLT-PET in oncology: current status and opportunities.
Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1659-72. doi: 10.1007/s00259-004-1687-6.
7
Positron emission tomography for prostate, bladder, and renal cancer.
Semin Nucl Med. 2004 Oct;34(4):274-92. doi: 10.1053/j.semnuclmed.2004.06.004.
9
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Nucl Med Commun. 2004 May;25(5):433-8. doi: 10.1097/00006231-200405000-00002.
10
11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.
Eur Urol. 2003 Jul;44(1):32-8; discussion 38-9. doi: 10.1016/s0302-2838(03)00207-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验